NANJING HANXIN INTERNATIONAL: GLP-1 import refusal records
Has FDA refused imports of GLP-1 products from NANJING HANXIN INTERNATIONAL?
Yes. FDA’s import refusal records list 1 refused shipment line declared as made by NANJING HANXIN INTERNATIONAL (China) whose FDA product code names semaglutide, on May 19, 2026. 1 of them carry a product code that FDA’s Import Alert 66-80 lists as a GLP-1 API or powder form.
- Country
- China
- City in FDA records
- Nanfaxin
- FEI numbers on the lines
- 3043275378
- Refused lines
- 1
- Lines with an Import Alert 66-80 API or powder code
- 1
- Drugs named in the product codes
- Semaglutide
- Refusal dates
- May 19, 2026
The declared manufacturer is the firm named on the import entry. A refusal is FDA’s decision on one shipment line; it is not a finding about the firm’s other products.
Import Alert 66-80’s Green List (published Oct 9, 2026) prints a redaction in place of every firm name, so this index cannot say whether NANJING HANXIN INTERNATIONAL is on it.
Refused shipment lines
| FDA refusal charges | Shipment ID | ||||
|---|---|---|---|---|---|
| May 19, 2026 | China | 61PCT72 SEMAGLUTIDE (ANTI-DIABETIC) | Active Pharm Ingred/Chems for Rx Compounding | DIRSEXMPT: The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it appears to be a drug within the meaning of Section 201(g) and it lacks adequate directions for use. FALSEDRUG: The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it appears to be a drug which is misbranded within the meaning of section 502(a)(1) in that its labeling is false or misleading. | 1FX-1577805-2/10003/1 |
FDA refusal charges on these lines
A line can carry several charges. Text is FDA’s charge statement, verbatim.
| DIRSEXMPT: The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it appears to be a drug within the meaning of Section 201(g) and it lacks adequate directions for use. | 1 |
| FALSEDRUG: The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it appears to be a drug which is misbranded within the meaning of section 502(a)(1) in that its labeling is false or misleading. | 1 |
This page lists public regulatory records as published by the issuing agency. A record is not a finding by this site. A warning letter states the agency’s view at the time it was issued; companies may have responded or corrected the issue since. Follow each link for the original document and any close-out letter. Report an error or add a company response.
Sources
Records last pulled Nov 15, 2026. Every entry links to the original public record.
1 line from FDA files read Nov 15, 2026.